Related Experiment Video
Updated: Jul 24, 2025
08:47
Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats
Published on: November 8, 2018
11.5K
Valproate overdose leading to hyperammonaemic encephalopathy.
Deepak S Sharma1, Sandeep Gupta2, Priyanka Sharma3
1Anaesthesia and Critical Care Medicine, Sandwell and West Birmingham NHS Trust, Birmingham, UK deepu84in@gmail.com.
BMJ Case Reports
|July 9, 2023
Summary
Sodium valproate overdose can cause hyperammonaemic encephalopathy. Prompt recognition and treatment, including supportive care and renal replacement therapy, are crucial for managing this serious side effect.
Area of Science:
- Neurology
- Clinical Toxicology
Background:
- Sodium valproate is a widely used anticonvulsant.
- Uncommon but serious side effects include hyperammonaemia and encephalopathy.
Observation:
- A male patient in his early 50s presented with collapse and an empty sodium valproate bottle.
- The patient developed hyperammonaemic encephalopathy secondary to sodium valproate overdose.
Findings:
- Hyperammonaemic encephalopathy is a potential complication of sodium valproate overdose.
- Supportive care and renal replacement therapy were effective in managing the patient's condition.
Implications:
- Clinicians must be aware of the risk of hyperammonaemic encephalopathy with sodium valproate.
- Early diagnosis and intervention are vital for favorable outcomes in sodium valproate overdose cases.
Related Concept Videos
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
467
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
467
01:26Anticholinesterase Agents: Poisoning and Treatment
925
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
925
01:14Antiepileptic Drugs: Glutamate Antagonists
427
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
427
01:14Prevention of Further Absorption of Poison
863
In cases of acute poisoning, the primary objective is to prevent further absorption of the toxic substance into the body. Immediate interventions using various decontamination techniques targeting the gastrointestinal (GI) tract can achieve this. Decontamination is crucial to prevent poison from entering the systemic circulation, which involves washing affected areas with water and mild soap and removing contaminated clothing. Once external decontamination is done, attention must be turned to...
863
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
350
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
350
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
208
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
208